Host: E. coli • AA: 1-475 (full length) • Tag: N-terminal His and MBP • MW: 52.2 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SARS-CoV-2 Envelope Protein (C40A, C43A, C44A mutant; recombinant)

Item No. 40875

Product Insert (PDF)
Technical Information
Synonyms
  • SARS-CoV-2 E Protein
  • SARS-CoV-2 Envelope Small Membrane Protein
  • SARS-CoV-2 sM Protein
  • Severe Acute Respiratory Syndrome Coronavirus 2 Envelope Protein
Purity
≥90% estimated by SDS-PAGE
Source
Recombinant SARS-CoV-2 N-terminal His- and MBP-tagged E protein (C40A, C43A, C44A mutant) expressed in E. coli
Amino Acids
1-475
MW
52.2 kDa
Formulation (Request formulation change)
Lyophilized from sterile PBS, pH 7.4
UniProt Accession №
P0DTC4
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    100 µg

    $493

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus, a member of the Betacoronavirus genus, and the causative agent of COVID-19.1,2,3 The SARS-CoV-2 genome contains approximately 30 kilobases and 14 open reading frames (ORFs) that encode four structural proteins: spike, envelope, membrane, and nucleocapsid, as well as 16 non-structural proteins and nine accessory factors.4 The SARS-CoV-2 envelope protein (E protein) is composed of an N-terminal domain, a transmembrane domain, and a C-terminal domain, which contains three conserved cysteine residues (C40, C43, and C44) that are post-translationally palmitoylated in a similar virus, SARS-CoV.5,6 It localizes to the Golgi, endoplasmic reticulum (ER), and ER-Golgi intermedium compartment (ERGIC) of SARS-CoV-2 infected cells and homo-oligomerization of the E protein forms a pH-sensitive, cation-selective ion channel, also known as a viroporin.7,5 It is involved in morphogenesis, viral assembly, and maturation and retention of the spike glycoprotein, also known as surface glycoprotein.5,8 SARS-CoV-2 E protein is acetylated by the histone acetyltransferase p300, and acetylated SARS-CoV-2 E protein binds to bromodomain-containing protein 4 (BRD4).9 Intravenous administration of recombinant SARS-CoV-2 E protein induces spleen edema, as well as pulmonary inflammatory cell infiltration, edema, interstitial hyperemia, hemorrhage, and alveolar collapse in mice.10 Cayman’s SARS-CoV-2 Envelope Protein (C40A, C43A, C44A mutant; recombinant) protein consists of 475 amino acids and has a calculated molecular weight of 52.2 kDa.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kandeel, M., Ibrahim, A., Fayez, M., et al. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J. Med. Virol. 92(6), 660-666 (2020).

    2. Lu, R., Zhao, X., Li, J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395(10224), 565-574 (2020).

    3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., et al. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci. 24(4), 2012-2019 (2020).

    4. Romano, M., Ruggiero, A., Squeglia, F., et al. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9(5), 1267 (2020).

    5. Santos-Mendoza, T. The envelope (E) protein of SARS-CoV-2 as a pharmacological target. Viruses 15(4), 1000 (2023).

    6. Liao, Y., Yuan, Q., Torres, J., et al. Biochemical and functional characterization of the membrane association and membrane permeabilizing activity of the severe acute respiratory syndrome coronavirus envelope protein. Virology 349(2), 264-275 (2006).

    7. Cabrera-Garcia, D., Bekdash, R., Abbott, G.W., et al. The envelope protein of SARS-CoV-2 increases intra-Golgi pH and forms a cation channel that is regulated by pH. J. Physiol. 599(11), 2851-2868 (2021).

    8. Boson, B., Legros, V., Zhou, B., et al. The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. The Journal of Biological Chemisty 296, 100111 (2021).

    9. Vann, K.R., Acharya, A., Jang, S.M., et al. Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection. Structure 30(9), 1224-1232 (2022).

    10. Xia, B., Shen, X., He, Y., et al. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. Cell Res. 31(8), 847-860 (2021).